385
Participants
Start Date
August 12, 2022
Primary Completion Date
December 29, 2028
Study Completion Date
December 29, 2028
JNJ-90014496
JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
Calvary Mater Newcastle Hospital, Waratah
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
St Vincents Hospital Melbourne, Fitzroy
RECRUITING
Odense University Hospital, Odense
RECRUITING
Fiona Stanley Hospital, Murdoch
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Hosp Univ Fund Jimenez Diaz, Madrid
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
University of Kentucky Medical Center, Lexington
RECRUITING
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
University of Iowa Hospital and Clinics, Iowa City
RECRUITING
Texas Transplant Institute, San Antonio
RECRUITING
St. David's South Austin Medical Center, Austin
RECRUITING
Colorado Blood Cancer Institute, Denver
RECRUITING
City of Hope, Duarte
RECRUITING
Swedish Cancer Institute, Seattle
RECRUITING
Rutgers Cancer Institute of New Jersey, Piscataway
RECRUITING
Princess Margaret Cancer Centre University Health Network, Toronto
RECRUITING
Erasmus MC, Rotterdam
RECRUITING
UMC Utrecht, Utrecht
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Hosp Univ Vall D Hebron, Barcelona
RECRUITING
Hosp Clinic de Barcelona, Barcelona
RECRUITING
ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona
RECRUITING
University College London Hospitals, London
RECRUITING
The Christie NHS Foundation Trust Christie Hospital, Manchester
Janssen Research & Development, LLC
INDUSTRY